As the Editor-in-Chief of Clinical and Molecular Hepatology (CMH), I am thrilled and honored to celebrate the publication of the “Korean Association for the Study of the Liver (KASL) Clinical Practice Guideline for Noninvasive Tests To Assess Liver Fibrosis in Chronic Liver Disease” in our journal. This comprehensive work marks a pivotal advance in hepatology, showcasing the dedicated efforts of the Guideline Development Committee.

The significance of this guideline is profound, particularly its discussion of the pressing need for noninvasive evaluation techniques when managing chronic liver disease (CLD). Accurate assessment of liver fibrosis is paramount, and this guideline offers evidence-based recommendations that skillfully blend international best practices with specific considerations for the Korean healthcare landscape. The development process is equally commendable in its combination of systematic literature reviews, meta-analyses, and expert consensus where evidence was scant. This thorough approach has produced guidelines that are both scientifically robust and clinically applicable, ensuring their relevance and utility across diverse medical settings. The end result is a resource of immense value to healthcare providers worldwide.

As the official journal of the KASL, CMH has long been an important channel for hepatology knowledge dissemination. The inclusion of this guideline further cements CMH’s position as a preeminent hepatology journal in Asia and beyond. It exemplifies our commitment to publishing influential, high-quality research that directly affects patient care and advances our understanding of liver diseases.

I extend my heartfelt congratulations on this remarkable achievement. It is a privilege for CMH to serve as the platform for sharing this crucial work with the global medical community. I eagerly anticipate the positive influence this guideline will have on clinical practices, patient outcomes, and future hepatology research.

Citations to this article as recorded by